photo [Congress] FOP Drug Development Forum (DDF) - 13-14 November - Orlando, FL - USA 

Oncodesign has been working for several years on its proprietary platform Nanocyclix® giving access to highly potent and selective kinase inhibitors and with intrinsic drug-like properties.. Through research activities conducted since 2014, Oncodesign has identified ALK2 kinase inhibitors demonstrating significant activity in phenotypic cellular tests related to FOP pathology. This work has been conducted in collaboration with world-renowned research institutes in the field.

Join Drug Development Forum (DDF) in Orlando to meet scientist leaders in FOP. Indeed, with 3 active FOP clinical trials, & an abundance of ongoing preclinical and basic research, this year’s DDF is not to be missed.

Benefit from this unique opportunity to expand your knowledge in rare disease. You will also be able to meet our CSO, Jan Hoflack, who will be presenting promising results on ALK2 inhibitors.

Identification of Potent & Selective Nanocyclix-based ALK2 inhibitors for use as potential FOP therapeutics
 13-14 November
 all day long

I fix a meeting!

I read the Press Release related to the scientific publication

%MCEPASTEBIN%

[Congress] European Bioanalysis Forum (EBF) – 20-22 Novembre - Barcelone - Espagne

EBF 2019 Oncodesign

Join Dr. Mouhssin Oufir – Head of DMPK & Bioanalytical Sciences Department – and, Cécile Olivarius – Business Account Manager - during the poster session disclosing our expertise in QTPA  (Quantitative targeted absolute proteomics).
Oncodesign’s exclusive MS2Plex® offering quantifies membrane proteins in a GLP environment such as CYPs, UGTs, ABC and SLC carriers involved in ADME-T studies for drug candidates.

[POSTER] « Quantitative Targeted Absolute Proteomics (QTAP) analysis of transporters for the validation of an in vitro Blood Brain Barrier model”

Mouhssin and Cécile will be thrilled to answer your questions about our ADME services for your projects:

  • Early ADME (in vitro & in vivo models)
  • Animal PK & Metabolism
  • Human PK & Metabolism
  • Metabolism
  • Drug-drug interaction
  • Immunogenicity
  • Bioanalysis

I want to know more!

[Congress] ELRIG Drug Discovery – 5-6 November - Liverpool - UK

ELRIG 2019 Oncodesign

Are you looking for an innovative company that guides you in the development of your molecule from the early stages?

For over 25 years, we have been developing technology platforms to support translational research from the early stages of the Drug Discovery process - a real driver of innovation acceleration and success for your molecule.

Mike Brown - Sales Manager - will be there to listen to you and find out about our offerings in oncology, immunology, dermatology, inflammatory and infectious diseases.

Discover our expertise on the exclusive MS2Plex offering presented in the poster below:

[POSTER 8] « Quantitative Targeted Absolute Proteomics (QTAP) analysis of transporters for the validation of an in vitro Blood Brain Barrier model”

Join us to discuss fast & efficient Drug Discovery tools available at Oncodesign to support your discovery programs from hit ID to IND!

[POSTER 36]"Nanocyclix: Next Generation of Kinase Therapeutics, a Chemocentric Approach for the Discovery of Selective Kinase Inhibitors”

This email address is being protected from spambots. You need JavaScript enabled to view it.

[Congress] AAPS – PharmSci 360 – 3-6 November - San Antonio - USA

APPS 2019 Oncodesign

Dr. Mouhssin Oufir and Dr. Carol Gebert will be present at the AAPS PharmSci 360 to propose you all our offerings to study the metabolism and pharmacokinetics of your drug candidates (chemical or biological entity), from their selection to approval by the regulatory authorities.

Challenge our expert team! We accompany you on all projects and design customized project, if needed, to take your molecule to the next step.

This email address is being protected from spambots. You need JavaScript enabled to view it.

By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.